《慢性移植物抗宿主病诊断与治疗中国专家共识（2021年版）》 - Suppr

Suppr

超能文献

[Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)].

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2021 Apr 14;42(4):265-275. doi: 10.3760/cma.j.issn.0253-2727.2021.04.001.

DOI:10.3760/cma.j.issn.0253-2727.2021.04.001

PMID:33979969

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8120129/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5a5/8120129/26557ee8973c/cjh-42-04-265-g001.jpg

相似文献

[Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)].《慢性移植物抗宿主病诊断与治疗中国专家共识（2021年版）》

Zhonghua Xue Ye Xue Za Zhi. 2021 Apr 14;42(4):265-275. doi: 10.3760/cma.j.issn.0253-2727.2021.04.001.

[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)].《慢性移植物抗宿主病诊断与治疗中国专家共识（2024年版）》

Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):713-726. doi: 10.3760/cma.j.cn121090-20240611-00217.

[Management of the chronic graft versus host disease: Guidelines from the Francophone society of bone marrow transplantation and cellular therapies (SFGM-TC)].[慢性移植物抗宿主病的管理：法语国家骨髓移植和细胞治疗协会（SFGM-TC）指南]

Bull Cancer. 2017 Dec;104(12S):S145-S168. doi: 10.1016/j.bulcan.2017.10.023. Epub 2017 Nov 24.

Optimal management of chronic graft-versus-host disease in children.儿童慢性移植物抗宿主病的最佳治疗策略。

Br J Haematol. 2010 Aug;150(3):278-92. doi: 10.1111/j.1365-2141.2010.08247.x. Epub 2010 Jun 10.

[Complications of hematopoietic stem cell transplantation and the treatment: graft-versus-host disease].[造血干细胞移植的并发症及治疗：移植物抗宿主病]

Nihon Naika Gakkai Zasshi. 2005 Jul 10;94(7):1337-43. doi: 10.2169/naika.94.1337.

[2018 update on chronic graft-versus-host disease].[2018年慢性移植物抗宿主病的最新进展]

Rinsho Ketsueki. 2018;59(10):2300-2306. doi: 10.11406/rinketsu.59.2300.

How I treat chronic graft-versus-host disease.我如何治疗慢性移植物抗宿主病。

Blood. 2001 Mar 1;97(5):1196-201. doi: 10.1182/blood.v97.5.1196.

Vulvovaginal Graft-Versus-Host Disease.外阴阴道移植物抗宿主病。

Obstet Gynecol Clin North Am. 2017 Sep;44(3):475-492. doi: 10.1016/j.ogc.2017.05.007.

Biology and management of chronic graft-versus-host disease.慢性移植物抗宿主病的生物学特性与管理

Cancer Treat Res. 2009;144:277-98. doi: 10.1007/978-0-387-78580-6_12.

[Complications of hematopoietic stem cell transplantation: physiopathology and management. 2. Graft-versus-host disease (GVHD)].[造血干细胞移植的并发症：病理生理学与管理。2. 移植物抗宿主病（GVHD）]

Nihon Naika Gakkai Zasshi. 1998 Aug 10;87(8):1502-9.

引用本文的文献

PD-1 inhibitor in patients with minimal residual disease who failed donor lymphocyte infusion or interferon after allogeneic haematopoietic stem cell transplantation.在异基因造血干细胞移植后接受供体淋巴细胞输注或干扰素治疗失败的微小残留病患者中使用程序性死亡受体1（PD-1）抑制剂。

Blood Cell Ther. 2025 May 25;8(2):200-209. doi: 10.31547/bct-2024-034.

Belumosudil in pediatric patients with chronic graft-versus-host disease after failed multi-line therapy: a case series.多线治疗失败后，贝利莫司汀在小儿慢性移植物抗宿主病患者中的应用：病例系列

Ann Hematol. 2025 Feb;104(2):1241-1247. doi: 10.1007/s00277-024-06128-6. Epub 2024 Dec 11.

Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research.Haploidentical 造血干细胞移植作为儿科重型再生障碍性贫血一线治疗：单中心研究。

Int J Med Sci. 2024 Apr 15;21(6):1027-1036. doi: 10.7150/ijms.94012. eCollection 2024.

[Clinical study of the cytokine panel in the diagnosis of ocular chronic graft-versus-host disease].[细胞因子检测在眼部慢性移植物抗宿主病诊断中的临床研究]

Zhonghua Xue Ye Xue Za Zhi. 2024 Mar 14;45(3):242-248. doi: 10.3760/cma.j.cn121090-20231031-00242.

[Evaluation of differences in quality of life in patients with chronic graft-versus-host disease].[慢性移植物抗宿主病患者生活质量差异的评估]

Zhonghua Xue Ye Xue Za Zhi. 2024 Jan 14;45(1):54-61. doi: 10.3760/cma.j.cn121090-20231008-00162.

Immune Reconstitution in Pediatric Aplastic Anemia after Allogeneic Hematopoietic Stem-cell Transplantation.异基因造血干细胞移植后儿童再生障碍性贫血的免疫重建。

Int J Med Sci. 2022 May 1;19(5):821-828. doi: 10.7150/ijms.70146. eCollection 2022.

本文引用的文献

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.芦可替尼用于异基因造血干细胞移植后类固醇难治性慢性移植物抗宿主病的评估。

JAMA Netw Open. 2021 Jan 4;4(1):e2034750. doi: 10.1001/jamanetworkopen.2020.34750.

The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside.mTOR抑制剂在血液系统疾病中的作用：从实验台到病床边

Front Oncol. 2021 Jan 8;10:611690. doi: 10.3389/fonc.2020.611690. eCollection 2020.

Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study.抗胸腺细胞球蛋白用于血液系统恶性肿瘤患者的同胞供者移植：一项多中心、开放标签、随机对照研究。

J Clin Oncol. 2020 Oct 10;38(29):3367-3376. doi: 10.1200/JCO.20.00150. Epub 2020 Jul 10.

Sirolimus as Rescue Therapy for Refractory/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study.西罗莫司作为难治性/复发性免疫性血小板减少症的挽救疗法：一项单中心、前瞻性、单臂研究的结果

Front Med (Lausanne). 2020 Mar 31;7:110. doi: 10.3389/fmed.2020.00110. eCollection 2020.

Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution.在单家机构过去 15 年的研究中，T 细胞耗竭的单倍体相合造血细胞移植的存活率得到了提高。

Bone Marrow Transplant. 2020 May;55(5):929-938. doi: 10.1038/s41409-019-0750-7. Epub 2019 Nov 18.

Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study.两种剂量水平的兔抗胸腺细胞球蛋白用于单倍体造血干细胞移植中的移植物抗宿主病预防：一项多中心随机研究。

BMC Med. 2019 Aug 12;17(1):156. doi: 10.1186/s12916-019-1393-7.

Allogeneic Bone Marrow Transplantation versus Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in Children: A Systematic Review and Meta-Analysis.异基因骨髓移植与外周血干细胞移植治疗儿童血液系统恶性肿瘤的系统评价和Meta分析

Biol Blood Marrow Transplant. 2020 Jan;26(1):88-93. doi: 10.1016/j.bbmt.2019.07.025. Epub 2019 Aug 5.

IL-22 Accelerates Thymus Regeneration via Stat3/Mcl-1 and Decreases Chronic Graft-versus-Host Disease in Mice after Allotransplants.IL-22 通过 Stat3/Mcl-1 加速胸腺再生，并降低小鼠同种异体移植后慢性移植物抗宿主病的发生。

Biol Blood Marrow Transplant. 2019 Oct;25(10):1911-1919. doi: 10.1016/j.bbmt.2019.06.002. Epub 2019 Jun 10.

Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.造血细胞移植后糖皮质激素难治性移植物抗宿主病患者接受芦可替尼治疗的疗效、毒性和感染并发症。

Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694. doi: 10.1016/j.bbmt.2019.04.003. Epub 2019 Apr 6.

Ruxolitinib for Therapy of Graft-versus-Host Disease.芦可替尼治疗移植物抗宿主病。

Biomed Res Int. 2019 Mar 6;2019:8163780. doi: 10.1155/2019/8163780. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验